GTx, Inc. (GTXI)-758 Poster Presentation of Phase II Trial Data in Advanced Prostate Cancer Selected as One of the Best Posters at the 28th Annual European Association of Urology Congress
3/19/2013 9:41:32 AM
MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (NASDAQ: GTXI) announced today that its poster presentation entitled, “GTx-758, an ERa agonist, reduces serum free testosterone lower than can be achieved by leuprolide with a significantly lower rate of hot flashes in men with advanced prostate cancer”, was selected as one of the best posters at the 28th Annual European Association of Urology Congress held in Milan, Italy, which commenced March 15, 2013. The presentation was held on Saturday, March 16, 2013 in Milan, Italy, in the session on new therapies in castration resistant prostate cancer. The data being presented represents findings from completed Phase II clinical studies of men with advanced prostate cancer examining the ability of GTx-758 (Capesaris®) to further reduce the levels of unbound, or “free”, testosterone to potentially limit the cancer’s advancement to castration resistant prostate cancer. Even with maximal suppression of free testosterone, GTx-758 may also, by replacing estrogen, provide the prospect for an improved quality of life with a better side effect profile than what is more typically experienced by men with advanced prostate cancer treated with commonly utilized forms of androgen deprivation therapy. GTx is currently enrolling a Phase II clinical study (G200712) to evaluate the safety and effectiveness of lower doses of GTx-758 to treat men with metastatic castration resistant prostate cancer and expects to receive topline data from this study later this year.
comments powered by